{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:41Z","timestamp":1790674121073,"version":"4.1.0"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.579523","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T05:22:12Z","timestamp":1605590532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient"],"prefix":"10.3389","volume":"11","author":[{"given":"Andrea","family":"Boutros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Schiavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guadagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Teresa","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Murdaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.10001","article-title":"Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600\u2013mutant melanoma: Five-year analysis of COMBI-AD","volume":"38","author":"Hauschild","year":"2020","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1468955","article-title":"Immunological effects of BRAF+MEK inhibition","volume":"7","author":"Ascierto","year":"2018","journal-title":"Oncoimmunology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S320","DOI":"10.1016\/j.annder.2017.09.540","article-title":"Hypersensibilit\u00e9 retard\u00e9e aux tatouages induite par un traitement combin\u00e9 anti-BRAF\u2013anti-MEK","volume":"144","author":"Rohmer","year":"2017","journal-title":"Annales Dermatol V\u00e9n\u00e9r\u00e9ol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"B6","article-title":"Cutaneous intolerance to tattoos in a patient with human immunodeficiency virus: a manifestation of the immune restoration syndrome","volume":"137","author":"Silvestre","year":"2001","journal-title":"Arch Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Transl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.08.019","article-title":"Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy","volume":"136","author":"Kuske","year":"2018","journal-title":"Pharmacol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"Dummer","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.579523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T05:22:13Z","timestamp":1605590533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.579523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":9,"alternative-id":["10.3389\/fimmu.2020.579523"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.579523","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"article-number":"579523"}}